AbbVie: FDA Approves VUITY 1.25%, First and Only Eye Drop to Treat Presbyopia

 Allergan, an AbbVie (NYSE: ABBV) company, today announced the U.S. Food and Drug Administration (FDA) approval of VUITY™ (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. VUITY is the first and only FDA-approved eye drop to treat this common and progressive eye condition that affects 128 million Americans, nearly half of the U.S. adult population.

https://www.streetinsider.com/Corporate+News/AbbVie+%28ABBV%29+Announces+FDA+Approval+of+VUITY+1.25%25%2C+the+First+and+Only+Eye+Drop+to+Treat+Presbyopia/19131846.html